Database→Semax

Tier 3CognitiveNeuroprotectionNootropicPREMIUM

Semax

Semax (MEHFPGP) -- Synthetic ACTH(4-7) Analog, Nootropic and Neuroprotective Heptapeptide

Approved in Russia and Ukraine as prescription intranasal medication for ischemic stroke, optic nerve atrophy, dyscirculatory encephalopathy, and cognitive decline. Listed on the Russian List of Vital and Essential Drugs (2011). Trade names: Semax 0.1% and Semax 1% nasal drops. Not FDA-approved. Not EMA-approved. No IND filed in the United States. Not on WADA Prohibited List.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-7) N-terminal fragment, stabilized with a Pro-Gly-Pro C-terminal extension. It retains the neurotrophic and neuroprotective properties of ACTH fragments without any adrenocortical hormonal activity. Approved in Russia and Ukraine since the 1990s for stroke, optic nerve disease, and cognitive decline. Human clinical data includes a 30-patient stroke trial (Gusev et al., 1997), a 110-patient BDNF/rehabilitation study (Gusev et al., 2018), and a 24-subject placebo-controlled fMRI study in healthy volunteers (Lebedeva et al., 2018). All evidence is Russian-origin with no Western GCP replication.

🔒

Full Profile: Premium Members Only

The complete Semax profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use